WT1, MSH6, GATA5 and PAX5 as epigenetic oral squamous cell carcinoma biomarkers - a short report
- 4 August 2016
- journal article
- other
- Published by Springer Nature in Cellular Oncology
- Vol. 39 (6) , 573-582
Abstract
Purpose Oral squamous cell carcinoma (OSCC) is a frequently occurring aggressive malignancy with a heterogeneous clinical behavior. Based on the paucity of specific early diagnostic and prognostic biomarkers, which hampers the appropriate treatment and, ultimately the development of novel targeted therapies, we aimed at identifying such biomarkers through a genetic and epigenetic analysis of these tumors. Methods 93 primary OSCCs were subjected to DNA copy number alteration (CNA) and methylation status analyses using methylation-specific multiplex ligation-dependent probe amplification (MS-MPLA). The genetic and epigenetic OSCC profiles obtained were associated with the patients’ clinic-pathological features. Results We found that WT1 gene promoter methylation is a predictor of a better prognosis and that MSH6 and GATA5 gene promoter methylation serve as predictors of a worse prognosis. GATA5 gene promoter methylation was found to be significantly associated with a shorter survival rate. In addition, we found that PAX5 gene promoter methylation was significantly associated with tongue tumors. To the best of our knowledge, this is the first study that highlights this specific set of genes as epigenetic diagnostic and prognostic biomarkers in OSCC. Conclusions Our data highlight the importance of epigenetically assessing OSCCs to identify key genes that may serve as diagnostic and prognostic biomarkers and, potentially, as candidate therapeutic targets.Keywords
Funding Information
- Portuguese Foundation for Science and Technology (SFRH/BD/52290/2013, UID/NEU/04539/2013)
This publication has 33 references indexed in Scilit:
- Validation of methylation markers for diagnosis of oral cavity cancerEuropean Journal of Cancer, 2015
- Key tumor suppressor genes inactivated by “greater promoter” methylation and somatic mutations in head and neck cancerEpigenetics, 2014
- Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cellsCellular Oncology, 2014
- GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinomaOncology Reports, 2014
- Decreased GATA5 mRNA expression associates with CpG island methylation and shortened recurrence-free survival in clear cell renal cell carcinomaBMC Cancer, 2014
- Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer managementOncoTargets and Therapy, 2013
- GATA Transcription Factors and CancerGenes & Cancer, 2010
- Prediction of Treatment Response in Head and Neck Cancer by Magnetic Resonance Spectroscopy2005
- Methylation-Specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequencesNucleic Acids Research, 2005
- Neck Dissection Classification UpdateJAMA Otolaryngology–Head & Neck Surgery, 2002